VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that include the acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma.

The post VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’ appeared first on MedCity News.

Leave a Replay

Sign up for our Newsletter

Contact Us